SG11201400293UA - Glycosylated polypeptide and drug composition containing said polypeptide - Google Patents
Glycosylated polypeptide and drug composition containing said polypeptideInfo
- Publication number
- SG11201400293UA SG11201400293UA SG11201400293UA SG11201400293UA SG11201400293UA SG 11201400293U A SG11201400293U A SG 11201400293UA SG 11201400293U A SG11201400293U A SG 11201400293UA SG 11201400293U A SG11201400293U A SG 11201400293UA SG 11201400293U A SG11201400293U A SG 11201400293UA
- Authority
- SG
- Singapore
- Prior art keywords
- polypeptide
- composition containing
- drug composition
- glycosylated
- glycosylated polypeptide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/655—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/655—Somatostatins
- C07K14/6555—Somatostatins at least 1 amino acid in D-form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011192203 | 2011-09-04 | ||
PCT/JP2012/072383 WO2013032012A1 (en) | 2011-09-04 | 2012-09-03 | Glycosylated polypeptide and drug composition containing said polypeptide |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201400293UA true SG11201400293UA (en) | 2014-08-28 |
Family
ID=47756484
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201400293UA SG11201400293UA (en) | 2011-09-04 | 2012-09-03 | Glycosylated polypeptide and drug composition containing said polypeptide |
SG10201601327RA SG10201601327RA (en) | 2011-09-04 | 2012-09-03 | Glycosylated polypeptide and drug composition containing said polypeptide |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201601327RA SG10201601327RA (en) | 2011-09-04 | 2012-09-03 | Glycosylated polypeptide and drug composition containing said polypeptide |
Country Status (12)
Country | Link |
---|---|
US (2) | US9441024B2 (en) |
EP (1) | EP2752425A4 (en) |
JP (2) | JP6211418B2 (en) |
KR (1) | KR102175017B1 (en) |
CN (2) | CN106146649B (en) |
AU (1) | AU2012302637B2 (en) |
BR (1) | BR112014004936A2 (en) |
CA (1) | CA2847336C (en) |
RU (1) | RU2627184C2 (en) |
SG (2) | SG11201400293UA (en) |
TW (1) | TWI631142B (en) |
WO (1) | WO2013032012A1 (en) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2597975C2 (en) * | 2011-03-04 | 2016-09-20 | Глитек, Инк. | Method for producing sialic acid-containing sugar chain |
US9977188B2 (en) | 2011-08-30 | 2018-05-22 | Skorpios Technologies, Inc. | Integrated photonics mode expander |
CN106146649B (en) * | 2011-09-04 | 2020-09-01 | 株式会社糖锁工学研究所 | Polypeptide having sugar chain attached thereto and pharmaceutical composition containing the same |
US9422357B2 (en) * | 2011-09-04 | 2016-08-23 | Glytech, Inc. | Glycosylated polypeptide and drug composition containing said polypeptide |
WO2014089365A1 (en) | 2012-12-07 | 2014-06-12 | Venatorx Pharmaceuticals, Inc | Beta-lactamase inhibitors |
CN105209033B (en) | 2013-03-14 | 2018-09-18 | 马萨诸塞大学 | Inhibit cataract and presbyopic method |
US9944658B2 (en) | 2013-03-14 | 2018-04-17 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
US9664855B2 (en) | 2014-03-07 | 2017-05-30 | Skorpios Technologies, Inc. | Wide shoulder, high order mode filter for thick-silicon waveguides |
WO2015183992A1 (en) | 2014-05-27 | 2015-12-03 | Skorpios Technologies, Inc. | Waveguide mode expander using amorphous silicon |
KR20180083378A (en) | 2015-11-13 | 2018-07-20 | 유니버시티 오브 매사추세츠 | Bifunctional molecules, including PEG for use in cataracts and presbyopia |
WO2017100537A1 (en) | 2015-12-10 | 2017-06-15 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
JP2019218265A (en) * | 2016-09-14 | 2019-12-26 | 生化学工業株式会社 | Method for enhancing blood retentivity of peptide |
US10649148B2 (en) | 2017-10-25 | 2020-05-12 | Skorpios Technologies, Inc. | Multistage spot size converter in silicon photonics |
US11360263B2 (en) | 2019-01-31 | 2022-06-14 | Skorpios Technologies. Inc. | Self-aligned spot size converter |
AU2021284284A1 (en) * | 2020-06-02 | 2022-11-17 | Entrinsic, LLC | Formulations and methods for treating diarrhea |
CN116655906B (en) * | 2023-04-13 | 2024-03-29 | 大连理工大学 | Sulfated glycopeptide, preparation method and antiviral application |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4380953A (en) | 1978-09-11 | 1983-04-26 | Filper Corporation | Transfer mechanism in a peach pitter |
US4235886A (en) | 1979-10-31 | 1980-11-25 | Merck & Co., Inc. | Cyclic hexapeptide somatostatin analogs |
US4310518A (en) | 1979-10-31 | 1982-01-12 | Merck & Co., Inc. | Cyclic hexapeptide somatostatin analogs |
US4280953A (en) * | 1979-11-08 | 1981-07-28 | The Salk Institute For Biological Studies | Glycosylated analogs of somatostatin |
US4316891A (en) | 1980-06-14 | 1982-02-23 | The Salk Institute For Biological Studies | Extended N-terminal somatostatin |
LU85269A1 (en) | 1984-03-26 | 1985-10-14 | Techland S A | NOVEL SOMATOSTATIN COMPOUNDS, PROCESS FOR THEIR SYNTHESIS, PREPARATION FOR VETERINARY USE CONTAINING SAID COMPOUNDS AND PROCESS FOR THE TREATMENT OF ANIMALS |
HU906341D0 (en) | 1986-10-13 | 1991-04-29 | Sandoz Ag | Process for producing peptonic derivatives modified with sugar and pharmaceutical preparatives containing these compounds as active substance |
PH30995A (en) * | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
IT1277391B1 (en) * | 1995-07-28 | 1997-11-10 | Romano Deghenghi | CYCLIC PEPTIDES ANALOGUE OF SOMATOSTATIN TO ACTIVITY INHIBITING THE GROWTH HORMONE |
US5750499A (en) | 1995-10-18 | 1998-05-12 | The Salk Institute For Biological Studies | Receptor-selective somatostatin analogs |
FI965181A (en) * | 1996-12-20 | 1998-06-21 | Map Medical Technologies Oy | Polyalcohol peptide derivatives |
JP3385947B2 (en) | 1998-01-05 | 2003-03-10 | 松下電器産業株式会社 | Bulk feeder |
AU2002254691B8 (en) * | 2001-04-23 | 2008-02-14 | Mallinckrodt Inc. | Tc and Re labeler radioactive glycosylated octreotide derivatives |
WO2003008431A1 (en) | 2001-06-19 | 2003-01-30 | Otsuka Chemical Co.,Ltd. | Process for producing sugar chain asparagine derivative |
US7943763B2 (en) | 2002-07-05 | 2011-05-17 | Otsuka Chemical Holdings Co., Ltd. | Process for preparing glycopeptides having asparagine-linked oligosaccharides, and the glycopeptides |
TWI330641B (en) | 2002-12-24 | 2010-09-21 | Yasuhiro Kajihara | Sugar chain asparagine derivatives |
KR100661212B1 (en) | 2002-12-26 | 2007-04-16 | 오츠카 가가쿠 가부시키가이샤 | Three-branched sugar-chain asparagine derivatives, the sugar-chain asparagines, the sugar chains, and processes for producing these |
ES2701175T3 (en) | 2003-02-04 | 2019-02-21 | Glytech Inc | Process to produce asparagine derivative of sugar chain |
JPWO2004101619A1 (en) * | 2003-05-15 | 2006-10-26 | 塩野義製薬株式会社 | Rational design and synthesis of functional glycopeptides |
JP4607017B2 (en) | 2003-07-28 | 2011-01-05 | 大塚化学株式会社 | Aminated complex type sugar chain derivative and method for producing the same |
TWI342880B (en) | 2005-07-19 | 2011-06-01 | Otsuka Chemical Co Ltd | Method for producing sugar chain derivatives, and sugar chain derivatives |
PT2225271E (en) * | 2007-12-03 | 2013-09-27 | Italfarmaco Spa | New non-selective somatostatin analogues |
AU2009261441B2 (en) * | 2008-06-17 | 2013-01-10 | Glytech, Inc. | Oligosaccharide chain added glp-1 peptide |
EP2294080A2 (en) * | 2008-06-27 | 2011-03-16 | Novo Nordisk Health Care AG | N-glycosylated human growth hormone with prolonged circulatory half-life |
CN106146649B (en) * | 2011-09-04 | 2020-09-01 | 株式会社糖锁工学研究所 | Polypeptide having sugar chain attached thereto and pharmaceutical composition containing the same |
US9422357B2 (en) | 2011-09-04 | 2016-08-23 | Glytech, Inc. | Glycosylated polypeptide and drug composition containing said polypeptide |
-
2012
- 2012-09-03 CN CN201610515602.XA patent/CN106146649B/en active Active
- 2012-09-03 WO PCT/JP2012/072383 patent/WO2013032012A1/en active Application Filing
- 2012-09-03 SG SG11201400293UA patent/SG11201400293UA/en unknown
- 2012-09-03 AU AU2012302637A patent/AU2012302637B2/en active Active
- 2012-09-03 US US14/342,360 patent/US9441024B2/en active Active
- 2012-09-03 KR KR1020147008136A patent/KR102175017B1/en active IP Right Grant
- 2012-09-03 BR BR112014004936A patent/BR112014004936A2/en not_active Application Discontinuation
- 2012-09-03 EP EP12828871.9A patent/EP2752425A4/en not_active Ceased
- 2012-09-03 RU RU2014112044A patent/RU2627184C2/en active
- 2012-09-03 JP JP2013531455A patent/JP6211418B2/en active Active
- 2012-09-03 CN CN201280053558.5A patent/CN103946234B/en active Active
- 2012-09-03 CA CA2847336A patent/CA2847336C/en active Active
- 2012-09-03 SG SG10201601327RA patent/SG10201601327RA/en unknown
- 2012-09-04 TW TW101132258A patent/TWI631142B/en active
-
2016
- 2016-07-19 US US15/213,872 patent/US9802996B2/en active Active
-
2017
- 2017-02-08 JP JP2017021710A patent/JP2017088615A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2013032012A1 (en) | 2013-03-07 |
RU2014112044A (en) | 2015-11-27 |
KR102175017B1 (en) | 2020-11-05 |
BR112014004936A2 (en) | 2017-04-04 |
SG10201601327RA (en) | 2016-03-30 |
US9441024B2 (en) | 2016-09-13 |
RU2627184C2 (en) | 2017-08-03 |
JP6211418B2 (en) | 2017-10-11 |
JPWO2013032012A1 (en) | 2015-03-23 |
AU2012302637B2 (en) | 2016-09-15 |
EP2752425A1 (en) | 2014-07-09 |
US20160368961A1 (en) | 2016-12-22 |
US9802996B2 (en) | 2017-10-31 |
AU2012302637A1 (en) | 2014-03-20 |
KR20140060548A (en) | 2014-05-20 |
TWI631142B (en) | 2018-08-01 |
CN106146649A (en) | 2016-11-23 |
CN103946234A (en) | 2014-07-23 |
JP2017088615A (en) | 2017-05-25 |
US20140315800A1 (en) | 2014-10-23 |
CN106146649B (en) | 2020-09-01 |
CA2847336A1 (en) | 2013-03-07 |
EP2752425A4 (en) | 2015-04-22 |
TW201315743A (en) | 2013-04-16 |
CA2847336C (en) | 2021-09-07 |
CN103946234B (en) | 2017-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL262667B (en) | An isolated polynucleotide encoding a polypeptide and a pharmaceutical composition comprising the isolated polynucleotide | |
SG10201601327RA (en) | Glycosylated polypeptide and drug composition containing said polypeptide | |
HK1199889A1 (en) | Relaxin fusion polypeptides and uses thereof | |
ZA201305504B (en) | Compositions containing glycosylated antibodies and uses thereof | |
EP2728002A4 (en) | Heterodimerized polypeptide | |
EP2718317A4 (en) | Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof | |
IL279676A (en) | Recombinant proteins and their therapeutic uses | |
EP2738255A4 (en) | Erap1-derived peptide and use thereof | |
SG11201405578TA (en) | Pharmaceutical composition containing peptide | |
ZA201302113B (en) | Caspofungin composition | |
EP2775831A4 (en) | Pharmaceutical compositions and uses thereof | |
ZA201207375B (en) | Stabilized pharmaceutical composition | |
SG11201402139UA (en) | High mast2-affinity polypeptides and uses thereof | |
EP2666482A4 (en) | Particle composition and pharmaceutical composition using particle composition | |
HK1198910A1 (en) | Pharmaceutical composition comprising ebastine and fluticasone | |
SG10201601324VA (en) | Glycosylated polypeptide and drug composition containing said polypeptide | |
SG10201602076QA (en) | Glycosylated polypeptide and pharmaceutical composition containing same | |
IL221501A (en) | Pharmaceutical composition comprising myramistin | |
PL2918267T3 (en) | Particulate pharmaceutical composition | |
EP2751129A4 (en) | Protein p14 with anti-cancer and anti-allergy activity and pharmaceutical composition comprising the same | |
ZA201309537B (en) | Pharmaceutical composition comprising fexofedine |